scispace - formally typeset
M

Mark S. Cragg

Researcher at University of Southampton

Publications -  249
Citations -  18184

Mark S. Cragg is an academic researcher from University of Southampton. The author has contributed to research in topics: Antibody & Monoclonal antibody. The author has an hindex of 55, co-authored 229 publications receiving 15768 citations. Previous affiliations of Mark S. Cragg include Royal Bournemouth Hospital & Walter and Eliza Hall Institute of Medical Research.

Papers
More filters
Journal ArticleDOI

Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Daniel J. Klionsky, +2522 more
- 21 Jan 2016 - 
TL;DR: In this paper, the authors present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macro-autophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes.
Journal ArticleDOI

Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas

TL;DR: With increasing evidence that mAb therapeutic activity in vivo depends on complement activation, these new CD20 reagents with their slow off-rates and increased potency in CDC hold considerable promise for improved clinical activity.
Journal ArticleDOI

Mechanisms of killing by anti-CD20 monoclonal antibodies.

TL;DR: How monoclonal antibodies (mAb) have driven research in the immunotherapy field over the last decade are discussed, their likely modes of action and their limitations in terms of effector exhaustion are explored, and ways in which they might be enhanced and further exploited in the future are explored.
Journal ArticleDOI

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

TL;DR: It is shown that the ability of mAbs to translocate CD20 into low-density, detergent-insoluble membrane rafts appears to control how effectively they mediate complement lysis of lymphoma cells.